Who Is Vanina Popova? Chief Development Officer, GH Research PLC
Popova holds an MD and leads clinical development of GH001 into pivotal programs. GH Research announcement
Vanina Popova, MD, is Chief Development Officer at GH Research PLC, where she leads the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement
At Mind Medicine Law, we track the people building legal, evidence-based access to psychedelic medicine: the companies running the trials, the researchers and advocates behind them, and the officials who write and run the laws.
Popova spent more than 20 years in global pharmaceutical research and development at Johnson & Johnson. She served as a clinical lead in the Spravato (esketamine) program and led its TRANSFORM-2 trial. GH Research announcement
Where Vanina Popova Is Now
- Current role: Chief Development Officer. GH Research announcement
- Organization: GH Research PLC. GH Research announcement
- Known for: Serving as a clinical lead in the Spravato (esketamine) program and leading TRANSFORM-2. GH Research announcement
- Recent news: GH Research PLC announced her appointment on November 13, 2026. GH Research announcement
GH Research PLC appointed Popova on November 13, 2026, to lead GH001 clinical development into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement
Career
Popova worked for more than 20 years in global pharmaceutical research and development at Johnson & Johnson. Her neuroscience career there began with 12 years in global clinical operations before she moved into clinical development. GH Research announcement
According to GH Research’s announcement, Popova led TRANSFORM-2, a pivotal Phase 3 trial that supported the approval of Spravato in treatment-resistant depression. She was involved in the early design of an esketamine monotherapy trial and co-authored its publication in JAMA Psychiatry. GH Research announcement
November 2026 Appointment
On November 13, 2026, GH Research PLC announced Popova’s appointment as Chief Development Officer. The announced role covers clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement
What Vanina Popova Leads
Popova will lead the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. She stated that she looks forward to guiding that work. GH Research announcement
Frequently asked questions
Who is Vanina Popova?
Vanina Popova, MD, is Chief Development Officer at GH Research PLC. GH Research announcement
When was Vanina Popova appointed Chief Development Officer?
GH Research appointed her on November 13, 2026. GH Research announcement
What does Vanina Popova lead at GH Research PLC?
She leads the clinical development of GH001 into pivotal programs in treatment-resistant depression and postpartum depression. GH Research announcement
Where did Vanina Popova work before GH Research PLC?
She worked for more than 20 years in global pharmaceutical research and development at Johnson & Johnson. GH Research announcement
What was Vanina Popova’s role in the Spravato program?
She served as a clinical lead in the Spravato (esketamine) program and led TRANSFORM-2. GH Research announcement
Does Vanina Popova hold an MD?
Yes. GH Research’s announcement identifies her as Vanina Popova, MD. GH Research announcement
Sources
General information compiled from the public reporting cited above, not medical or legal advice. Mention of a treatment, trial or bill is not a claim that it is safe, effective or legal where you live. Not endorsed by or affiliated with Vanina Popova or GH Research. See more people in psychedelic medicine.